Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00 at Deutsche Bank Aktiengesellschaft

Pediatrix Medical Group (NYSE:MD) had its price target lifted by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a report published on Monday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

A number of other analysts have also issued reports on the stock. UBS Group boosted their target price on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research note on Friday, August 9th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday. Truist Financial raised their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday. Finally, Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their price target for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Down 0.3 %

Shares of MD opened at $16.03 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a market cap of $1.38 billion, a P/E ratio of -5.24, a P/E/G ratio of 2.35 and a beta of 1.55. The company’s fifty day simple moving average is $11.99 and its 200-day simple moving average is $9.59.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the company earned $0.29 EPS. As a group, analysts expect that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insiders Place Their Bets

In other news, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the transaction, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now directly owns 175,347 shares in the company, valued at approximately $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,538 shares of company stock worth $373,664. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP lifted its position in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. raised its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after purchasing an additional 455,785 shares during the last quarter. Boston Partners lifted its holdings in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Cubist Systematic Strategies LLC boosted its position in Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group in the 2nd quarter worth approximately $1,721,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.